Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.
Charles BobinYasmine IddirCharlotte ButterworthJulien Masliah PlanchonAlexandra Saint-CharlesAngela BelliniJaydutt BhalshankarGaëlle PierronValérie CombaretValerie AttignonAnne Isabelle BertozziNadège CorradiniBenoit DumontLudovic MansuyCamille KhanfarSebastien KleinClaire BriandetDominique PlantazFrédéric MillotSandrine ThouveninIsabelle AertsLee Aymar Ndounga-DiakouSalim LaghouatiSamuel D AbbouNina JehannoHubert TissotShufang RenaultSylvain BaulandeVirginie RaynalLaurence BozecIvan BiècheOlivier O DelattrePablo BerlangaGudrun SchleiermacherPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
We demonstrate the clinical utility of combining ALK cfDNA ddPCR for disease monitoring and cfDNA WES for the study of clonal evolution and resistance mechanisms in patients with neuroblastoma receiving ALK-targeted therapy.